Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS postdoc Loren Kell recently attended the British Society for Research on Ageing (BSRA) annual scientific meeting, where she won the prestigious Korenchevsky Prize for her presentation.

Loren Kell

At the BSRA meeting, held in Manchester, Loren presented the research she carried out as a DPhil student, and now a postdoc, at NDORMS. Her presentation, titled “The mTOR-ment of ageing”, explored how the mTOR inhibitor rapamycin, one of the most potent life-extending drugs known to date, enhances resilience against DNA damage in the ageing immune system.

As the winner of the first place Korenchevsky Prize, the BSRA will fund Loren to attend and present her work at the American Aging Association’s Annual conference in 2026 in Utah.

On receiving the award, Loren said, “I’m really pleased for my work to be recognised by this generous award, and I’m excited to be going to the US next year to connect with fellow gerontologists who are doing some fantastic research”.

Loren joined the Alsaleh Group within NDORMS in 2022 during her DPhil at the Department of Biochemistry. Her work has investigated human immune system ageing throughout both her BSc Immunology and Infection at University College London, and during her DPhil at NDORMS and Biochemistry. She is now continuing her research as a postdoc, focusing on interventions that rejuvenate immune responses in old age by their ability to modulate mTOR activity, DNA damage, and cell senescence.

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8th October 2026.

Adam Croft appointed Norman Collisson Professor of Musculoskeletal Science

This appointment brings a further focus to linking rheumatology discovery science and clinical trials in NDORMS, strengthening translational rheumatology research across the department to deliver transformative treatments for patients with inflammatory arthritis.

NIHR fellowship to support national trial evaluating rehabilitation after kneecap dislocation

Dr Colin Forde has been awarded a National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Postdoctoral Award to lead a national study evaluating rehabilitation for people with a kneecap (patellar) dislocation.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Professor Afsie Sabokbar retires after more than 30 years at NDORMS

Botnar Institute Director of Graduate Studies, Professor Afsie Sabokbar, is retiring after more than 30 years at NDORMS.

Researchers funded to cure – rather than manage – inflammatory disease

Researchers from the Kennedy Institute of Rheumatology will join international partners in a bid to transform how chronic inflammatory disease is treated.